New Insights on How Some Small-Cell Lung Cancers can Become Chemo-Resistant

Intratumoral differences or heterogeneity can be blamed for chemo-resistance in small-cell lung cancer patients, finds a new study.

Poor clinical outcomes are mainly due to chemotherapy-resistant small cell lung cancer, which often accounts for nearly 14 percent of all lung cancers. Certain changes in tumor differences could be the reason behind chemo-resistance. The findings of this study were discussed at American Association for Cancer Research Annual Meeting 2018.

"There have been few therapeutic advances in the past 30 years, and platinum-based chemotherapy remains the standard of care. As a result, five-year survival is less than 7 percent across all stages," said Lauren Byers, M.D., associate professor of Thoracic Head & Neck Medical Oncology, and the study’s principal investigator. "Most patients respond well to platinum chemotherapy initially, but relapse within a few months. There are no highly effective second-line therapies."

New Genetic Subtype of Lung Cancer Defined by Massachusetts General Study
The Massachusetts General Hospital (MGH) Cancer Center’s investigators’ report has defined the role of a recently keyed gene abnormality in a lethal form of lung cancer.

‘Further understanding of small cell lung cancer affecting intratumoral heterogeneity (ITH) is important to identify populations of cells that may drive certain pathways associated with aggressive resistance to chemotherapy.’

The challenge in studying why and how SCLC chemoresistance occurs is due to the fact that most patients do not undergo another biopsy or surgery at the time of cancer recurrence. This leaves investigators like Byers and Stewart with few SCLC samples with which to conduct genomic and biomarker analyses of drug-resistant tumors.

To overcome the lack of SCLC samples, the team developed novel disease models by isolating circulating tumor cells from a simple blood draw. The cells, placed under the mouse’s skin, develop tumors representative of the patient from whom they were derived.

These SCLC models, called circulating tumor cell-derived xenografts (CDX), are unique to each patient and provide an opportunity to assess treatment response to novel targeted therapies, as well as changes that may occur in response to therapy.

Breast Cancer Driver, HER2, in 3 Percent of Lung Cancers
Out of 920 patients,24(3 percent) with advanced-stage lung cancer had mutations in the gene HER2 has been reported by The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center.

"We hypothesize that differences in gene and protein expression between tumor cells, called intratumoral heterogeneity, contribute to the rapid development of platinum chemotherapy resistance," said Stewart. "This means that there are likely multiple cell populations in SCLC patients who have not yet been treated. Some of those cells may be killed by chemotherapy but others will not. These resistant cells then continue to grow and prevent further response to treatment."

To study intratumoral heterogeneity (ITH) in SCLC, the investigators performed single-cell sequencing of CDX models to identify gene expression differences between individual cells from chemotherapy-sensitive CDX tumors compared to those that remain resistant.

Triple-Therapy Treatment May Help Fight Resistant Lung Cancers
A new study in mice has shown that cancers with KRAS-related gene mutations might benefit from a triple therapy with two experimental drugs plus radiation therapy.

"We conducted single-cell RNA sequencing to determine if ITH exists and to compare the response to chemotherapy in the CDX and the patient," said Stewart. "We found several distinctions between sensitive and resistant models detected at the single-cell level, which testified to single cell sequencing’s potential usefulness for understanding how these cancers may develop resistance."

SCLC has a variety of differences at the cellular and genetic level, from the way genes are expressed to which cell-signaling pathways are involved. These differences between tumor cells result in ITH. A more thorough understanding of ITH is important to identify populations of cells that may drive certain pathways associated with aggressive resistance to chemotherapy.

Non-Small Cell Lung Cancers can be Sorted in Clusters
Researchers from University of Texas used three endocytic pathways as markers to sort out 29 non-small cell lung cancer (NSCLC) lines into two distinct clusters.

The team also found that SCLC models sensitive to chemotherapy had more cells that expressed two genes, ASCL1 and DLL3, while those that were chemoresistant had fewer cells expressing those genes or had undergone a process called epithelial-to-mesenchymal transition (EMT), which also has been shown to play a role in therapy resistance in other cancers.

"Cells expressing each of these characteristics were identified across all tumors, suggesting cells sensitive or resistant to chemotherapy are both present in the same tumor," said Stewart. "However, even subtle shifts in the distribution of these genes can exert a significant impact on response to treatment."

Stewart adds that the team’s data support further use of single-cell analysis to explore the role of ITH in SCLC, including effects of treatment on cell populations.

"Through the use of these new mouse models, we report data that supports use of single-cell analysis to explore the role of ITH as a driver of drug resistance," said Stewart.

Source-Eurekalert